1. Kim C, Kim Y, Yang DW, et al. Direct and indirect costs of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul) 2019;82:27–34.
3. Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 2002;57:48–64.
4. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62:1081–1087.
6. Giembycz MA, Newton R. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype. Clin Chest Med 2014;35:203–217.
8. Dunne AE, Kawamatawong T, Fenwick PS, et al. Direct inhibitory effect of the PDE4 inhibitor roflumilast on neutrophil migration in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2019;60:445–453.
10. Lambert JA, Raju SV, Tang LP, et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol 2014;50:549–558.
13. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010;120:76–85.
14. Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2014;134:314–322.
16. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685–694.
17. Martinez FJ, Rabe KF, Calverley PM, et al. Determinants of response to roflumilast in severe chronic obstructive pulmonary disease: pooled analysis of two randomized trials. Am J Respir Crit Care Med 2018;198:1268–1278.
18. Rabe KF, Watz H, Baraldo S, et al. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. Lancet Respir Med 2018;6:827–836.
19. Kim SW, Kim JH, Park CK, et al. Effect of roflumilast on airway remodelling in a murine model of chronic asthma. Clin Exp Allergy 2016;46:754–763.
20. Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting β2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND): a randomized clinical trial. Am J Respir Crit Care Med 2016;194:559–567.
21. Rabe KF, Calverley PM, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J 2017;50:1700158.
23. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797–799.
24. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013;144:758–765.
32. Mackay AJ, Patel AR, Singh R, et al. Randomized double- blind controlled trial of roflumilast at acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:656–659.
34. Moretto N, Caruso P, Bosco R, et al. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. J Pharmacol Exp Ther 2015;352:559–567.
35. Lea S, Metryka A, Li J, et al. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. Cytokine 2019;123:154739.
36. Myou S, Fujimura M, Kamio Y, et al. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 1999;160:817–820.
38. Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563–571.
41. Rhee CK, Chau NQ, Yunus F, Matsunaga K, Perng DW; on behalf the COPD Assembly of the APSR. Management of COPD in Asia: a position statement of the Asian Pacific Society of Respirology. Respirology 2019;24:1018–1025.